BridgeBio Oncology Therapeutics, Inc. (BBOT) Key Metrics
BBOT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $226.1M
- Enterprise value
- $109.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.65
BBOT key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBBOT returns How much profit the business earns on the capital it uses.
BBOT per-share figures Results divided by the shares outstanding at year-end.
BBOT financial health Debt, liquidity and how easily interest is covered.
BBOT valuation history
BBOT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BBOT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BBOT price vs earnings per share
BBOT key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $389.9M | — | — | — | — |
| Enterprise value | −$32.8M | — | — | — | — |
| Price / book | 0.9 | — | — | — | — |
| Earnings yield | −34.4% | — | — | — | — |
| Free cash flow yield | −29.4% | — | — | — | — |
| Share price at fiscal year-end | $12.52 | — | — | — | — |
| Per share | |||||
| Revenue per share | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$4.30 | — | −$3.16 | −$0.00 | −$0.00 |
| Operating cash flow per share | −$3.66 | — | −$2.54 | — | — |
| Free cash flow per share | −$3.68 | — | −$2.56 | — | — |
| Cash per share | $13.66 | — | $0.01 | — | — |
| Book value per share | $13.20 | — | −$0.00 | −$0.00 | −$0.00 |
| Tangible book value per share | $13.20 | — | −$0.00 | −$0.00 | −$0.00 |
| Capex per share | $0.02 | — | $0.02 | $0.00 | $0.00 |
| Debt per share | $0.09 | — | $0.00 | $0.00 | $0.00 |
| Shares outstanding | 31.1M | — | 20.5M | 20.5M | 20.5M |
| Change in shares outstanding | — | — | 0.0% | 0.0% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −44.7% | −78.7% | — | — | — |
| Return on invested capital (ROIC) | — | −68.4% | — | −14.0% | −184.1% |
| Return on assets (ROA) | −41.7% | −76.3% | — | −2.4% | −30.1% |
| Return on tangible assets | −29.9% | −38.2% | — | −2.4% | −30.1% |
| Financial health | |||||
| Total debt | $2.8M | — | $70,095 | $43,106 | $36,961 |
| Cash & short-term investments | $425.5M | $1.7M | $250,000 | — | — |
| Net debt | −$422.7M | −$1.7M | −$179,905 | $43,106 | $36,961 |
| Debt / equity | 0.01 | — | — | — | — |
| Debt / assets | 0.01 | — | 0.21 | 0.30 | 0.26 |
| Current ratio | 12.14 | 10.40 | 9.93 | — | — |
| Quick ratio | 12.14 | 10.40 | 9.93 | — | — |
| Working capital | $390.4M | $1.8M | $3.5M | — | — |
| Invested capital | −$11.6M | $187.0M | −$243,474 | $21,229 | $18,604 |
| Tangible asset value | $411.1M | $188.7M | −$63,569 | −$21,877 | −$18,357 |
| Net current asset value | $388.2M | −$3.8M | $3.5M | — | — |
| Graham net-net per share | $12.47 | — | −$0.01 | −$0.01 | −$0.01 |
| Capital allocation | |||||
| Capex / depreciation | 0.99 | 0.24 | 4.50 | 0.00 | 0.00 |
| Efficiency | |||||
| Days payables outstanding | 1,330.8 | — | — | — | — |
| Receivables turnover | 0.00 | — | — | — | — |
| Payables turnover | 0.27 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $386,000 | — | — | — | — |
| Average payables | $2.2M | $1.8M | $575,000 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BBOT's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BBOT valuation and financial ratios
BridgeBio Oncology Therapeutics earned a return on equity of −44.7% in fiscal 2025. It ended the year with $2.8 million of debt and $425.5 million in cash and short-term investments, a net cash position of $422.7 million. The share count rose 52.0% from 20.5M to 31.1M over 4 years.
See the BBOT income statement, the BBOT chart for price history, or the BBOT stock overview for the latest quote and news.
BBOT key metrics FAQ
What is BridgeBio Oncology Therapeutics's return on equity?
BridgeBio Oncology Therapeutics's return on equity (ROE) was −44.7% in fiscal 2025: net income of -$134.0 million on average shareholders' equity of $299.9 million.
How much debt does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics had total debt of $2.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is BridgeBio Oncology Therapeutics's free cash flow yield?
BridgeBio Oncology Therapeutics generated -$114.5 million of free cash flow in fiscal 2025, a free cash flow yield of −29.4% on its market value at year-end ($389.9 million).
What is BridgeBio Oncology Therapeutics's current ratio?
BridgeBio Oncology Therapeutics's current ratio was 12.14 at the end of fiscal 2025: current assets were 12.14 times current liabilities.